About IBA Radiopharma Solutions
Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them with global solutions, from project design to the operation of their facility. In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP radiopharmaceuticals production centers.
Ad Statistics
Times Displayed: 114061
Times Visited: 6783 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
About UZ Brussels
The radiopharmaceutical chemistry unit is part of the Nuclear Medicine department of the UZ Brussel and aims at the synthesis and production of both routine and newly developed radiolabelled molecules for the diagnosis and (therapy) of various disease. The radiopharmacy is directly linked with the cyclotron unit giving access to daily productions of cyclotron-based radioisotopes. UZ Brussel is part of the Brussels Imaging Pharmacy (BIP) and the Brussels RadioTheranostics Platform (BRTP), an established coordinated network of radiopharmacists, radiochemists, scientists and clinicians of 3 hospitals -UZ Brussel, IJ Bordet and ULB Erasme- in the Brussels region.
The availability of a wide range of diagnostic radiopharmaceuticals allows for more accurate and specific diagnosis and follow-up of patients. The development of targeted tracers for radionuclide therapy will offer more individualized patient treatment.
Back to HCB News
